About
Our mission
BioIntel is an independent editorial intelligence platform serving biotech leaders with signal-first analysis that helps teams make better decisions.
What we do
BioIntel helps biotech founders, investors, and operators stay ahead by turning complex scientific and market developments into clear, decision-useful signal.
Who it serves
Biotech & Biopharmaceutical Companies
Drug discovery, development, operations, and strategy.
AI in Medicine & Healthcare Technology
Machine learning applications and predictive analytics.
Investment Community
VC, private equity, and institutional investing in biotech and healthtech.
Research & Academia
Scientists, researchers, and university programs.
Regulatory & Business Development
FDA approvals, partnerships, and licensing deals.
Strategic Operators
Leaders navigating competitive intelligence and execution tradeoffs.
Core pillars
AI in Drug Discovery
Machine learning, predictive models, and computational biology.
Biopharmaceutical Industry
Drug development, clinical trials, and regulatory news.
Biotech Innovation
Gene therapy, CRISPR, synthetic biology, and emerging technologies.
Healthcare Investment
Funding rounds, M&A, IPOs, and market analysis.
Medical Technology
Digital health, diagnostics, and medical devices.
Regulatory & Policy
FDA approvals, healthcare policy, and compliance.
Editorial stance
BioIntel is research-driven and independent, combining clear writing with signal-first analysis and practical context for decision-makers.